Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
Ad26COVS1
BNT162b2
COVID-19
SARS-CoV-2
hemodialysis
vaccination
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
03
2022
accepted:
30
05
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
Due to the waning humoral response after a two-dose SARS-CoV-2 mRNA vaccination, a third booster was recommended in hemodialyis patients. Data on a heterologous mRNA-vector regimen, which might improve immunogenicity, are very limited. In this observational study 36 chronic hemodialysis patients (mean (SD) age 66.9 (15.9) years, 33.3% females) were followed up for 13 months. All patients were vaccinated twice using the mRNA-BNT162b2 vaccine, followed by a 3 The seroconversion rate was 47.2%, 100%, 69.4% and 100% one month after the 1 A third heterologous booster dose helped to sustain humoral immunity in almost all hemodialysis patients and induced a significant T-cellular response in half of them. Stimulating the immune response against SARS-CoV-2 by two different vaccine platforms seems to be a promising approach.
Sections du résumé
Background
Due to the waning humoral response after a two-dose SARS-CoV-2 mRNA vaccination, a third booster was recommended in hemodialyis patients. Data on a heterologous mRNA-vector regimen, which might improve immunogenicity, are very limited.
Methods
In this observational study 36 chronic hemodialysis patients (mean (SD) age 66.9 (15.9) years, 33.3% females) were followed up for 13 months. All patients were vaccinated twice using the mRNA-BNT162b2 vaccine, followed by a 3
Results
The seroconversion rate was 47.2%, 100%, 69.4% and 100% one month after the 1
Conclusions
A third heterologous booster dose helped to sustain humoral immunity in almost all hemodialysis patients and induced a significant T-cellular response in half of them. Stimulating the immune response against SARS-CoV-2 by two different vaccine platforms seems to be a promising approach.
Identifiants
pubmed: 35812459
doi: 10.3389/fimmu.2022.907615
pmc: PMC9261096
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
RNA, Messenger
0
Spike Glycoprotein, Coronavirus
0
Viral Vaccines
0
spike protein, SARS-CoV-2
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
907615Informations de copyright
Copyright © 2022 Davidovic, Schimpf, Abbassi-Nik, Stockinger, Sprenger-Mähr, Lhotta and Zitt.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nephrol Dial Transplant. 2022 Jun 23;37(7):1384-1386
pubmed: 35138374
Nat Med. 2021 Sep;27(9):1510-1511
pubmed: 34312555
Kidney Int. 2022 May;101(5):883-894
pubmed: 35176326
Nat Med. 2021 Sep;27(9):1530-1535
pubmed: 34312554
Am J Kidney Dis. 2022 Feb;79(2):185-192.e1
pubmed: 34508833
NPJ Vaccines. 2020 Sep 28;5:91
pubmed: 33083026
Kidney Int. 2022 Feb;101(2):390-402
pubmed: 34856313
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Lancet. 2022 Feb 26;399(10327):800-802
pubmed: 35065703
Front Immunol. 2021 Jun 16;12:704773
pubmed: 34220867
Vaccines (Basel). 2022 Mar 11;10(3):
pubmed: 35335065
Kidney Int. 2021 Dec;100(6):1334-1335
pubmed: 34656642
Nephrol Dial Transplant. 2022 Jan 25;37(2):390-392
pubmed: 34643714
N Engl J Med. 2022 Mar 17;386(11):1046-1057
pubmed: 35081293
Kidney Int. 2020 Dec;98(6):1540-1548
pubmed: 32979369
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983
pubmed: 33151337
Nat Med. 2022 Mar;28(3):486-489
pubmed: 35051989
Kidney Int. 2021 Sep;100(3):702-704
pubmed: 34216675
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Nat Med. 2021 Sep;27(9):1525-1529
pubmed: 34262158